Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Panagopoulos, Kiriaki ^a   Cross Knorr, Sam ^a   Dillard, Christen ^a   Pantazatos, Dionysios ^a   Del Tatto, Michael ^a   Mills, David ^a   Goldstein, Lisa ^b   Renzulli, Joseph ^b   Quesenberry, Peter ^a   Chatterjee, Devasis ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

Extracellular vesicles; Gene ontology; Liquid chromatography tandem mass spectrometry; Prostate cancer; Proteomics

Indexed keywords

PROHIBITIN; PROTEIN 14 3 3; PROTEIN HYDROLYSATE;

ARTICLE; CANCER CELL; CELL ISOLATION; CELL VACUOLE; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS SPECTROMETRY; PROSTATE CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS REGULATORY PROTEINS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION MEDIATORS; MALE; NEOPLASM GRADING; PHENOTYPE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEOME; SECRETORY VESICLES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84885009056     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-118     Document Type: Article

References (49)

1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523. 10.1016/S0022-5347(05)63946-8, 12544300.
2. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106. 10.1016/S0140-6736(02)09408-4, 12126818.
3. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92-02. J Clin Oncol 2003, 21:3972-3978. 10.1200/JCO.2003.11.023, 14581419.
4. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290. 10.1016/j.ijrobp.2004.08.047, 15817329.
5. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252. 10.1016/S0360-3016(01)01579-6, 11483335.
6. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006, 66:794-802. 10.1158/0008-5472.CAN-05-1716, 16424011.
7. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, Roninson IB. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci USA 2000, 97:4291-4296. 10.1073/pnas.97.8.4291, 18232, 10760295.
8. Currid CA, O'Connor DP, Chang BD, Gebus C, Harris N, Dawson KA, Dunn MJ, Pennington SR, Roninson IB, Gallagher WM. Proteomic analysis of factors released from p21-overexpressing tumour cells. Proteomics 2006, 6:3739-3753. 10.1002/pmic.200500787, 16739131.
9. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001, 98:12072-12077. 10.1073/pnas.211053698, 59769, 11593017.
10. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23:2919-2933. 10.1038/sj.onc.1207518, 15077154.
11. Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006, 107:102-108. 10.1016/j.imlet.2006.09.005, 17067686.
12. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis 2005, 35:169-173. 10.1016/j.bcmd.2005.07.001, 16081306.
13. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010, 123:1603-1611. 10.1242/jcs.064386, 2864708, 20445011.
14. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005, 92:305-311. 2361848, 15655551.
15. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006, 66:9290-9298. 10.1158/0008-5472.CAN-06-1819, 16982774.
16. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009, 69:5601-5609. 10.1158/0008-5472.CAN-08-3860, 2853876, 19549916.
17. Sandvig K, Llorente A. Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Mol Cell Proteomics 2012, 11:M111. 012914, 3394943, 22493179.
18. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 2004, 279:17515-17523. 10.1074/jbc.M313816200, 14766752.
19. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004, 64:8867-8875. 10.1158/0008-5472.CAN-04-2938, 15604246.
20. Renzulli JF, Del Tatto M, Dooner G, Aliotta J, Goldstein L, Dooner M, Colvin G, Chatterjee D, Quesenberry P. Microvesicle induction of prostate specific gene expression in normal human bone marrow cells. J Urol 2010, 184:2165-2171. 10.1016/j.juro.2010.06.119, 20850816.
21. Zhang H, Pelech S. Using protein microarrays to study phosphorylation-mediated signal transduction. Semin Cell Dev Biol 2012, 23:872-882. 10.1016/j.semcdb.2012.05.009, 22706299.
22. Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T. Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J 2012, 2:e60. 10.1038/bcj.2012.5, 3317524, 22829255.
23. Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 2011, 18:R103-R123. 10.1530/ERC-10-0343, 21565970.
24. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989, 49:5016-5022.
25. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 2009, 28:2796-2805. 10.1038/onc.2009.139, 3008357, 19483725.
26. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003, 3:931-943.
27. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer 2012, 131:49-58. 10.1002/ijc.26327, 3307948, 21796629.
28. Gaiffe E, Pretet JL, Launay S, Jacquin E, Saunier M, Hetzel G, Oudet P, Mougin C. Apoptotic HPV positive cancer cells exhibit transforming properties. PLoS One 2012, 7:e36766. 10.1371/journal.pone.0036766, 3344932, 22574222.
29. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004, 3:11-20. 10.1186/1476-4598-3-11, 14749471.
30. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142. 150969, 11994401.
31. Chatterjee D, Moen EL, Chin YE. Inhibition of STAT3 activation by RKIP in colon cancer. Forum on Immunopathological Diseases and Therapeutics 2011, 2:35-45.
32. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007, 18:1765-1773. 10.1093/annonc/mdm086, 17426060.
33. Bluyssen HA, Rastmanesh MM, Tilburgs C, Jie K, Wesseling S, Goumans MJ, Boer P, Joles JA, Braam B. IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol 2010, 299:C354-362. 10.1152/ajpcell.00513.2009, 20484656.
34. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 2012, 18:127-139. 10.1158/1078-0432.CCR-11-1889, 3251692, 22090359.
35. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem 2003, 278:13061-13068. 10.1074/jbc.M210015200, 12551925.
36. Chander H, Halpern M, Resnick-Silverman L, Manfredi JJ, Germain D. Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4. PLoS One 2011, 6:e22456. 10.1371/journal.pone.0022456, 3150379, 21829624.
37. Wang S, Nath N, Fusaro G, Chellappan S. Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol 1999, 19:7447-7460. 84738, 10523633.
38. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003, 278:47853-47861. 10.1074/jbc.M305171200, 14500729.
39. Sievers C, Billig G, Gottschalk K, Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS One 2010, 5:e12735. 10.1371/journal.pone.0012735, 2939069, 20856874.
40. Radhakrishnan VM, Martinez JD. 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS One 2010, 5:e11433. 10.1371/journal.pone.0011433, 2900177, 20628654.
41. Wang Z, Nesland JM, Suo Z, Trope CG, Holm R. The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3beta and epsilon are independent prognostic factors for these tumors. PLoS One 2011, 6:e24843. 10.1371/journal.pone.0024843, 3174199, 21935479.
42. Pan Y, Zhong LJ, Zhou H, Wang X, Chen K, Yang HP, Xiaokaiti Y, Maimaiti A, Jiang L, Li XJ. Roles of vimentin and 14-3-3 zeta/delta in the inhibitory effects of heparin on PC-3M cell proliferation and B16-F10-luc-G5 cells metastasis. Acta Pharmacol Sin 2012, 33:798-808. 10.1038/aps.2012.42, 22669117.
43. Murata T, Takayama K, Urano T, Fujimura T, Ashikari D, Obinata D, Horie-Inoue K, Takahashi S, Ouchi Y, Homma Y, Inoue S. 14-3-3zeta, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res 2012, 18:5617-5627. 10.1158/1078-0432.CCR-12-0281, 22904106.
44. Titus MA, Tan JA, Gregory CW, Ford OH, Subramanian RR, Fu H, Wilson EM, Mohler JL, French FS. 14-3-3{eta} amplifies androgen receptor actions in prostate cancer. Clin Cancer Res 2009, 15:7571-7581. 10.1158/1078-0432.CCR-08-1976, 2795092, 19996220.
45. Urano T, Takahashi S, Suzuki T, Fujimura T, Fujita M, Kumagai J, Horie-Inoue K, Sasano H, Kitamura T, Ouchi Y, Inoue S. 14-3-3sigma is down-regulated in human prostate cancer. Biochem Biophys Res Commun 2004, 319:795-800. 10.1016/j.bbrc.2004.05.056, 15184053.
46. Lodygin D, Diebold J, Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene 2004, 23:9034-9041. 10.1038/sj.onc.1208004, 15489902.
47. Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, Hancock JF. 14-3-3 facilitates Ras-dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol 1998, 18:3947-3955. 108979, 9632779.
48. Freed E, Symons M, Macdonald SG, McCormick F, Ruggieri R. Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 1994, 265:1713-1716. 10.1126/science.8085158, 8085158.
49. Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R, Albert S, Rajalingam K, Hekman M, Rapp UR. Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins. J Biol Chem 2009, 284:3183-3194.